J. Heathcote

发表

Hepatocellular carcinoma (HCC): a global perspective.

P. Malfertheiner, J. Bruix, M. Sherman, 2010, Journal of clinical gastroenterology.

Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C

T. Arenovich, S. Missiha, J. Heathcote, 2007, The American Journal of Gastroenterology.

Durability of Serological Remission in Chronic Hepatitis C Treated With Interferon-Alpha-2B

J. Heathcote, M. Krajden, C. Yim, 1998, American Journal of Gastroenterology.

Durability of serological remission in chronic hepatitis C treated with interferon-Alpha-2B

J. Heathcote, M. Krajden, C. Yim, 1998 .

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C

J. Heathcote, H. Sim, J. Wojcik, 1998, Journal of viral hepatitis.

Appendix 7: Screening for hepatitis C infection: evidence review f or newly arriving immigrants and refugees

K. Pottie, C. Greenaway, J. Heathcote, 2011 .

493 Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year

Ching-lung Lai, E. Gane, Y. Cheng, 2006 .

Consensus interferon: a novel interferon for the treatment of hepatitis C

J. Heathcote, 1998, Journal of viral hepatitis.

Screening for renal disease using serum creatinine: who are we missing?

O. Djurdjev, A. Levin, J. Heathcote, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy.

M. Sherman, R. Inman, G. Levy, 1990, Annals of internal medicine.

143 EFFICACY AND SAFETY OF INCREASING DOSES OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A IN TREATMENT NAIVE CHRONIC HCV PATIENTS

R. Crabbé, A. Horban, R. Flisiak, 2008 .

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.

P. Lambert, C. Siegrist, H. Davis, 2004, Vaccine.

CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study

C. Cooper, A. Krieg, H. Davis, 2004, Journal of Clinical Immunology.

A. Carpentier, D. Bigam, R. Croxford, 2000, Hepatology.

Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study.

M. Sherman, D. Ma, J. Allard, 2008, Journal of hepatology.

Cost‐effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis

T. Therneau, S. Gabriel, K. Lindor, 1999, Hepatology.

World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective.

P. Malfertheiner, J. Bruix, M. Sherman, 2010, Journal of gastrointestinal and liver diseases : JGLD.

Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

S. Zeuzem, K. Nieforth, J. Heathcote, 2001, Expert opinion on investigational drugs.

No association between hepatitis C and B‐cell lymphoma

F. Shepherd, B. Zanke, M. Moore, 1999, Hepatology.

988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM

E. Schiff, T. Berg, J. Albrecht, 2008 .

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.

M. Sherman, L. Cohen, J. Heathcote, 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy.

J. Heathcote, R. Uldall, P. Chan, 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A. Carpentier, D. Bigam, R. Croxford, 1999 .

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

G. Tomlinson, B. Bressler, J. Heathcote, 2001, Hepatology.

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

M. Buti, R. Goldin, J. Heathcote, 1999, Hepatology.

A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus

A. Sette, G. Minuk, T. Wright, 1999, Hepatology.

Weighty issues in hepatitis C

J. Heathcote, 2002, Gut.

À La Carte Interferon for Hepatitis C?

S. Sherlock, P. Marcellin, A. Lok, 2000, Hepatology.

Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon.

P. Milkiewicz, I. Pache, J. Heathcote, 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Interferon‐associated lymphocyte 2′,5′‐oligoadenylate synthetase in acute and chronic viral hepatitis

Young-In Kim, J. Heathcote, S. Read, 1989, Hepatology.

Variant syndromes of autoimmune hepatitis.

J. Heathcote, 2002, Clinics in liver disease.

Long term follow-up of patients with chronic hepatitis C treated with interferon alpha.

G. Minuk, J. Heathcote, M. Krajden, 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?

L. Blendis, K. Sniderman, S. Tobe, 1992, Journal of hepatology.

Hepatitis C viral infection in the immunosuppressed patient

J. Collier, J. Heathcote, 1998, Hepatology.

ISG 15 , a ubiquitin-like interferon-stimulated gene , promotes hepatitis C virus production in vitro : implications for chronic infection and response to treatment

Limin Chen, I. McGilvray, J. Heathcote, 2010 .

Lamivudine and intron a combination treatment in patients with chronic hepatitis B infection

A. Dhillon, J. Heathcote, S. Schalm, 1998 .

Management of hepatitis B.

J. Heathcote, H. Ko, David K. H. Wong, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102)

Roger Williams, J. George, S. Gordon, 2008 .

Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study)

Y. Liaw, Ching-lung Lai, E. Gane, 2005 .

Sociocultural factors that potentially affect the institution of prevention and treatment strategies for hepatitis B in Chinese Canadians

J. Heathcote, C. Yim, Harry Wu, 2009 .

When to treat patients with chronic hepatitis C

J. Heathcote, A. Ramji, 2004, Current gastroenterology reports.

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

A. Detsky, K. O'rourke, J. Heathcote, 1993, Annals of Internal Medicine.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

P. Marcellin, J. Albrecht, S. Zeuzem, 1998, Lancet.

MAID : An effect size based model for microarray data integration across laboratories and platforms

Zhaolei Zhang, Limin Chen, Aled M. Edwards, 2008, BMC Bioinformatics.

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

Katyna Borroto-Esoda, P. Marcellin, K. Kitrinos, 2011, Hepatology.

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

A. Dhillon, A. Dhillon, J. Heathcote, 2000, Gut.

, infection : a randomised trial treatment of patients with chronic hepatitis B Lamivudine and alpha interferon combination

A. Dhillon, J. Heathcote, S. Schalm, 2000 .

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

M. Manns, I. Mackay, R. Chapman, 1999, Journal of hepatology.

Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection.

R. Inman, J. Heathcote, J. Wright, 1986, Annals of internal medicine.

Unusual Infections Complicating the Use of Steroids with Severe Alcoholic Hepatitis: Report of 2 Cases

M. Sherman, J. Heathcote, V. Arantes, 1995 .

Tenofovir in the treatment of chronic hepatitis B

J. Heathcote, D. Yu, 2011 .

Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial

Y. Liaw, E. Gane, J. Heathcote, 2005 .

[124] 76 WEEK FOLLOW UP OF HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TELBIVUDINE, ADEFOVIR OR SWITCHED FROM ADEFOVIR TO TELBIVUDINE

P. Marcellin, G. Harb, Y. Chao, 2007 .

Treatment of HBe Antigen-Positive Chronic Hepatitis B

J. Heathcote, 2003, Seminars in liver disease.

Treatment of hepatitis C

J. Heathcote, J. Main, J. Heathcote, 2005, Journal of viral hepatitis.

52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis

P. Marcellin, G. Minuk, Y. Chao, 2006 .

Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year

Y. Liaw, E. Gane, J. Heathcote, 2006 .

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

R. D. de Man, H. Janssen, B. Hansen, 2003, Gut.

Durability of hbeag seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy

H. Janssen, B. Hansen, J. Heathcote, 2001 .

46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES)

P. Marcellin, S. Lim, M. Rizzetto, 2004 .

Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma

G. Tomlinson, M. Krahn, J. Heathcote, 2012, Journal of viral hepatitis.

Health state utilities and quality of life in patients with hepatitis B.

T. Einarson, G. Tomlinson, M. Sherman, 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy

P. Marcellin, Z. Goodman, S. Lim, 2006 .

Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C

G. Levy, J. Heathcote, I. Wanless, 1999, Journal of viral hepatitis.

689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR

A. Gładysz, P. Marcellin, S. Zeuzem, 2008 .

51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients

Y. Liaw, S. Zeuzem, E. Gane, 2006 .

The role of interferon in the treatment of viral hepatitis.

J. Heathcote, D. Wong, Jenny Heathcote, 1994, Pharmacology & therapeutics.

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment‐naïve hepatitis C patients

M. Pawłowska, R. Crabbé, A. Horban, 2009, Hepatology.

755 SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS

R. Crabbé, A. Horban, R. Flisiak, 2010 .

Results of lamivudine therapy for HBe antigen positive hepatitis (in the West).

J. Heathcote, 2003, Journal of Hepatology.

Dangers of immunosuppressive therapy in hepatitis B virus carriers.

J. Heathcote, E. Lueg, 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Determination of hepatitis B phenotype using biochemical and serological markers

William M. Lee, R. Fontana, A. Lok, 2017, Journal of viral hepatitis.

EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Willis C. Maddrey, H. Alter, Sheila Sherlock, 1999, Journal of hepatology.

Antiviral Therapy for Patients with Chronic Hepatitis C

J. Heathcote, 2000, Seminars in liver disease.

Treating chronic hepatitis C with pegylated interferon alfa‐2a (40 KD) and ribavirin in clinical practice

M. Sherman, K. Peltekian, E. Yoshida, 2006, Alimentary pharmacology & therapeutics.

Polymorphisms of HLA‐DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B

K. Simon, S. Zeuzem, U. Akarca, 2014, Alimentary pharmacology & therapeutics.

The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons.

Hemant A Shah, J. Heathcote, T. Tang, 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.

M. Krahn, J. Heathcote, M. Kapral, 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression.

G. Tomlinson, M. Krahn, A. John-Baptiste, 2010, Journal of hepatology.

Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin

J. Heathcote, W. Lam, S. Waheeb, 2001, The British journal of ophthalmology.

Retreatment of chronic hepatitis C: who and how?

J. Heathcote, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

Limin Chen, I. Borozan, J. Feld, 2005, Gastroenterology.

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C

G. Tomlinson, B. Bressler, J. Heathcote, 2003, Hepatology.

Sociocultural factors that potentially affect the institution of prevention and treatment strategies for prevention of hepatitis B in Chinese Canadians.

J. Heathcote, C. Yim, Harry Wu, 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Gene Expression Profiling of Acute Liver Stress During Living Donor Liver Transplantation

I. Borozan, I. McGilvray, D. Grant, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.

Limin Chen, I. Borozan, J. Feld, 2010, Gastroenterology.

Gene expression profiling of hepatocellular cancer identifies a consistent pattern in cancerous and distant liver tissue: Arguments for a field defect

S. Gallinger, Limin Chen, I. Borozan, 2005 .

Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection.

C. Rice, B. Lindenbach, G. Randall, 2006, Gastroenterology.

Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990

Murray Krahn, John B Wong, J. Wong, 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions

J. Rehm, B. Fischer, J. Heathcote, 2006, European journal of gastroenterology & hepatology.

ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.

Limin Chen, I. McGilvray, J. Heathcote, 2010, The Journal of general virology.